Warning Letter — Baxter International Inc.
The FDA Center for Drug Evaluation and Research issued a Warning Letter to Baxter International Inc. on September 29, 2026, following an evaluation of company operations.
This notice affects Baxter International Inc., specifically departments involved in drug manufacturing, quality systems, and regulatory compliance under CDER jurisdiction.
The issuance of a Warning Letter by CDER indicates significant regulatory concerns regarding compliance with federal standards. While the specific violations are not detailed in the provided excerpt, such letters typically necessitate rigorous remediation efforts and may lead to restricted product distribution or delayed approvals if not addressed to the agency's satisfaction.
Regulatory and Quality teams should conduct a thorough review of existing manufacturing and quality control systems to ensure alignment with CDER expectations. Immediate preparation for potential follow-up inspections or requests for corrective action plans is advisable.
FDA Warning Letter issued to: Baxter International Inc.. 09/29/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/baxter-international-inc-733231-09292026
Open in openFDA / FDA.gov